Payload Information
General Information of This Payload
| Payload ID | PAY0LZMST |
|||||
|---|---|---|---|---|---|---|
| Name | Maytansinoid DM3 |
|||||
| Synonyms |
Maytansinoid DM3; Maytansinoid DM 3; XNG6QZ89ZB; 796073-54-6; DM3; Maytansine, N2'-deacetyl-N2'-(4-mercapto-1-oxopentyl)-; N(2')-Deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine; UNII-XNG6QZ89ZB; SCHEMBL18757725; HY-130080; CS-0104939
Click to Show/Hide
|
|||||
| Target(s) | Microtubule (MT) | |||||
| Structure |
|
|||||
| Formula | C37H52ClN3O10S |
|||||
| Isosmiles | C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)S)C)\C)OC)(NC(=O)O2)O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C37H52ClN3O10S/c1-20-11-10-12-28(48-9)37(46)19-27(49-35(45)39-37)22(3)33-36(5,51-33)29(50-34(44)23(4)40(6)30(42)14-13-21(2)52)18-31(43)41(7)25-16-24(15-20)17-26(47-8)32(25)38/h10-12,16-17,21-23,27-29,33,46,52H,13-15,18-19H2,1-9H3,(H,39,45)/b12-10+,20-11+/t21?,22-,23+,27+,28-,29+,33+,36+,37+/m1/s1
|
|||||
| InChIKey |
LJFFDOBFKICLHN-IXWHRVGISA-N
|
|||||
| IUPAC Name |
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl(4-sulfanylpentanoyl)amino]propanoate
|
|||||
| Pharmaceutical Properties | Molecule Weight |
766.3 |
Polar area |
158 |
||
Complexity |
1380 |
xlogp Value |
3 |
|||
Heavy Count |
52 |
Rot Bonds |
9 |
|||
Hbond acc |
11 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Tmab-SSNPP-DM3 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 77.60% (Day 10) | High HER2 expression (HER2+++) | ||
| Method Description |
Mice bearing mammary tumor transplants from the MMTV-HER2 Fo5 line were given a single iv injection (10 mg/kg) of Tmab-SPP-DM1, Tmab-SSNPP-DM3, Tmab-SSNPP-DM4, Tmab-MCC-DM1, or vehicle (n=7 mice per group), and tumor growth was monitored for 25 days.
|
||||
| In Vivo Model | MMTV-HER2 Fo5 CDX model (Trastuzumab resistant) | ||||
| In Vitro Model | Breast cancer | MMTV-HER2 cells | Mus musculus | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.